The Latest
Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement Of LEQEMBI® (Lecanemab) For Early Alzheimer’s Disease
Canada’s drug regulator has issued a final positive review supporting public reimbursement of Leqembi (lecanemab) for early Alzheimer’s disease, marking a significant policy shift.